---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-012619"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:33:31.006994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M

## Summary
- First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.
- Net loss $28.1M ($0.21 per share) vs $33.2M ($0.34 per share) YoY improvement.
- Cash & investments $89.7M at March 31, 2022, down from $116.7M at Dec 31, 2021.
- FDA to convene advisory committee for XPHOZAH (phosphate binder) for hyperphosphatemia in CKD on dialysis.
- Amended Kyowa Kirin deal: up to $40M additional milestones; royalty rate reduced from high teens to low double digits.

## SEC filing metadata
- accession: 0001628280-22-012619
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/0001628280-22-012619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828022012619/ardx-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-012619
- JSON: https://secwatch.observer/filing/0001628280-22-012619.json
- Plain text: https://secwatch.observer/filing/0001628280-22-012619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.